Alembic Pharma Q1FY27 Net Profit Up 12% to ₹173 Crore; Revenue Surges 26% to ₹2,150 Crore on US Generics Growth

The Quick Take

• Alembic Pharmaceuticals reported Q1FY27 consolidated net profit of ₹173.07 crore, up 12.1% from ₹154.38 crore year-on-year, on strong performance across US generics and domestic branded formulations
• Revenue surged 25.7% year-on-year to ₹2,150 crore from ₹1,711 crore, significantly outpacing the bottom-line growth rate and signalling a volume-led expansion with margins under some investment pressure
• The results from two tier-2 sources confirm consistent Q1FY27 data and position Alembic as a mid-cap Indian pharma outperformer in a quarter where many peers face pricing and compliance challenges

Alembic Pharmaceuticals, the Baroda-based mid-size Indian pharmaceutical company, delivered solid Q1FY27 results with revenue growing 25.7% year-on-year to ₹2,150 crore against ₹1,711 crore in the prior year period. Consolidated net profit rose 12.1% to ₹173.07 crore from ₹154.38 crore, with both The Hindu BusinessLine and NDTV Profit confirming the numbers from independent reporting. The revenue growth rate of 25.7% significantly outpacing the 12.1% profit growth suggests the company is investing in capacity, sales force expansion or new product launches — generating top-line momentum but absorbing some of the revenue increment at the operating level before translating to the bottom line.

Alembic Pharma operates across two primary revenue streams: US generics — the largest segment, where the company files ANDAs with the FDA and launches generic versions of off-patent drugs — and domestic branded formulations, where it markets specialty medicines across cardiology, diabetes, anti-infectives and other chronic disease categories. The 25.7% revenue growth signals robust momentum in US generic drug launches, where Alembic has been building its pipeline through multiple ANDA filings annually. US generics revenue quality is influenced by the number of first-to-file opportunities, competitive intensity in approved products and the USD/INR exchange rate, which amplifies earnings in rupee terms during periods of rupee weakness.

For investors tracking Indian pharmaceutical mid-caps, Alembic's Q1FY27 performance — particularly the 25.7% revenue growth — stands out positively in a sector where US FDA compliance challenges and pricing pressure in some generic categories have created headwinds for peers. Key forward signals include the pace of new FDA approvals and US generic product launches, domestic formulation volume growth in chronic therapy segments, any FDA inspection outcomes for Alembic's manufacturing facilities, and management guidance on whether the revenue-to-profit gap narrows in Q2FY27 through operating leverage. The INR/USD trajectory remains a persistent factor influencing reported earnings.

Synthesized from 2 sources.